Navigation Links
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
Date:12/27/2007

ize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier, both developed and supplied to XTENT by Biosensors International Group. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent. XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of our most recent quarterly report on Form 10-Q for the quarter ended September 30, 2007. T
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. XTENT Announces Third Quarter 2007 Financial Results
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
4. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
7. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
10. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
11. Gentiva(R) Health Services Files Universal Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 North American ... PT Online Continuing Education Courses . ... hours of CME - TPTA, approval # 56399TX      ... evaluation of the shoulder complex - 10.5 hours - ... #56400TX , Examination and Treatment of the SI Joint ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 "Necrorun" was ... which takes a look at the latest and coolest ... Joe Troohey, the host of NewsWatch and technology expert, ... this is an entertaining endless runner game with knights, ... game was released in 2009, according to Eurogamer. The ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Jan. 3 Continuing its role as ... organizations, the,American Association of Preferred Provider Organizations ... Care Administrators Association,(HCAA) that will significantly enhance ... consolidation and increased consumerism continue to fuel,further ...
... and Hispanic ethnic groups and others with a family history of ... glaucoma are particularly vulnerable, ... have no early symptoms and do not notice as their peripheral,vision ... the,three million Americans with the disease are unaware of their condition.,January ...
... In an era of expanding competition,from generics, expiring ... in new drug discoveries, there is very little ... report by Kalorama Information entitled Drug,Pricing and Reimbursement ... companies the information they need to,reevaluate their pricing ...
... 3 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that a registration,statement covering the ... effective by the Securities and Exchange Commission on ... informational purposes only, and does not,represent a solicitation ...
... finds one-hour session produces as much carbon monoxide as a ... A leisurely hour of puffs from a hookah -- a ... -- packs the same carbon monoxide punch as a pack-a-day ... looks at a single toxic gas, making it impossible to ...
... Emory University have developed a novel anti-tumor compound that represents ... points" for cancer cells. , The results of research on ... of Cancer Research. The article is highlighted on the cover. ... human patients with solid tumors in 2007. , The idea ...
Cached Medicine News:Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 3Health News:Novel anticancer strategy moves from laboratory to clinic 2Health News:Novel anticancer strategy moves from laboratory to clinic 3
(Date:3/27/2015)... 27, 2015 The Temple Health & Bioscience District ... 5,000-square-foot building at 1802 South First St. in the Temple ... the City of Temple to receive ... the Central Texas Veterans Health Care System, the new facility ... early stage biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
(Date:3/27/2015)... LAS VEGAS , March 27, 2015 Zimmer ... more efficient external fixation system for trauma patients. ... the XtraFix ® External Fixation System from ... design technology and materials.   The XtraFix ... and clamps from the external fixation process, resulting in saved ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... Transdermal System CIII 20 mcg/hour provided significantly ... compared to Butrans 5 mcg/hour when used in opioid-experienced ... according to a pivotal Phase 3 clinical study published ... of Pain . (Logo: http://photos.prnewswire.com/prnh/20100921/NY67262) ...
... SILVER SPRING, Md., Sept. 23, 2011 The U.S. ... treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a ... kidney (renal) failure and is also associated with increased ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Atypical HUS accounts ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6FDA Approves Soliris for Rare Pediatric Blood Disorder 2FDA Approves Soliris for Rare Pediatric Blood Disorder 3
... EVLT, the #1 physician choice in ... advantages to remedying superficial vein reflux. EVLT ... to surgical vein stripping that effectively and ... laser fiber to occlude the vein. The ...
... Aculens 186 UV combines the latest technology ... measurement of ultra violet transmission and auto ... is also programmed to network with the ... Instruments, today, or in the future. , ...
Inquire...
...
Medicine Products: